Radiopharm Theranostics (ASX:RAD) received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer, according to a Tuesday filing with the Australian bourse.
Shares of the company fell past 4% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.